European Deep Brain Stimulation (DBS) Depression Study

Last updated: September 5, 2024
Sponsor: Abbott Medical Devices
Overall Status: Completed

Phase

N/A

Condition

Depression

Treatment

Deep Brain Stimulation

Clinical Study ID

NCT01331330
NM-09-035-EU-DB
  • Ages 21-70
  • All Genders

Study Summary

To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder (TR-MDD), single or recurrent episode on mood as measured by the MADRS.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women (non-pregnant) age is 21-70 years;

  • Diagnosed with non-psychotic major depressive disorder, single or recurrent episodeby Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition, TextRevision, 2000 (DSM-IV-TR) criteria derived from the Mini InternationalNeuropsychiatric Interview (MINI);

  • First episode onset before age 45;

  • Current episode > 12 month duration;

  • In the current episode: Documented resistance to a minimum of 4 adequate depressiontreatments from at least 3 different categories;

  • In adult lifetime (>21 year of age) have experience a period of wellness as definedby DSM IV criteria;

  • MADRS score ≥22 at 2 separate baseline visits, rated by 2 separate psychiatrists;

  • Global Assessment of Functioning (GAF) score <50;

  • Mini-mental state examination (MMSE) score >24;

  • No change in current antidepressant medication regimen or medication free for atleast 4 weeks prior to study entry;

  • Able to give informed consent in accordance with institutional policies;

Exclusion

Exclusion Criteria:

  • A diagnosis of bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived fromthe MINI;

  • Meets criteria for borderline or antisocial personality disorder in the last 12months by DSM-IV-TR criteria, derived from the Cluster B Personality DisordersSections 301.7 - 301.83, preferably screened via Structured Clinical Interview forDSM-IV Personality Disorders (SCID-II) at Baseline visit (optional);

  • In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;

Study Design

Total Participants: 9
Treatment Group(s): 1
Primary Treatment: Deep Brain Stimulation
Phase:
Study Start date:
May 01, 2011
Estimated Completion Date:
January 31, 2015

Study Description

The European Study was a prospective, multicenter, double-blind, randomized study comparing high frequency stimulation (130 Hz) to low frequency stimulation (20 Hz). Subjects underwent 2 baseline evaluations by 2 separate psychiatrists and were implanted with the Libra DBS system. Subjects were randomized to receive either high or low frequency stimulation. The primary endpoint was evaluated after 6 months of stimulation.

Connect with a study center

  • Paracelsus Medical University

    Salzburg, 5020
    Austria

    Site Not Available

  • CHU Pasteur

    Nice, 06002
    France

    Site Not Available

  • Hôpital La Pitié Salpêtrière

    Paris, 75651
    France

    Site Not Available

  • University Hospital

    Bonn, D-53105
    Germany

    Site Not Available

  • Hadassah-Hebrew University Medical Center

    Ein Karem, Jerusalem 91120
    Israel

    Site Not Available

  • Hadassah-Hebrew University Medical Center

    Jerusalem, 91120
    Israel

    Site Not Available

  • King's College London

    London, SE5 9RS
    United Kingdom

    Site Not Available

  • National Hospital for Neurology and Neurosurgery - UCL

    London, WC1N 3
    United Kingdom

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.